Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Delphi Genetics, a developer of new products and technologies for gene cloning and protein expression, and Eurogentec, a provider of products and services for life science research, have signed an agreement to co-market the use of StabyDNA technology for GMP manufacturing purposes.
Subscribe to our email newsletter
Under the agreement Eurogentec will promote Delphi Genetics’s StabyDNA technology for use in GMP manufacturing on an exclusive basis. The financial terms of the agreement were not disclosed.
The antibiotic resistance-gene free technology, developed and owned by Delphi Genetics allows for clone selection, plasmid stability and manufacturing of plasmids and proteins without the use of antibiotics.
Philippe Gabant, CEO of Delphi Genetics, said: “This collaboration will strongly contribute to the advancement of the StabyDNA technology for therapeutic applications. Eurogentec has the experience and know-how to manufacture biotherapeutics based on the StabyDNA technology and importantly has biotherapeutic manufacturing experience for all clinical phases.”